• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

头孢他啶-阿维巴坦成功治疗一名儿科重症患者的KPC-MDR败血症性休克。

Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient.

作者信息

Vargas Maria, Buonomo Antonio Riccardo, Buonanno Pasquale, Iacovazzo Carmine, Servillo Giuseppe

机构信息

Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Naples, Italy.

Department of Clinical Medicine and Surgery - Section of Infectious Diseases, University of Naples Federico II, Naples, Italy.

出版信息

IDCases. 2019 Sep 5;18:e00634. doi: 10.1016/j.idcr.2019.e00634. eCollection 2019.

DOI:10.1016/j.idcr.2019.e00634
PMID:31538046
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6745432/
Abstract

Ceftazidime-avibactam is a combination agent consisting of the β-lactamase inhibitor avibactam and the broad-spectrum cephalosporin ceftazidime. There are no published case reports or studies evaluating the use of CAZ-AVI in pediatric critically ill patients. We report a case of a successful treatment of septic shock due to (KP) in a 14-years-old boy (body weight 50 kg) admitted in intensive care unit (ICU).

摘要

头孢他啶-阿维巴坦是一种由β-内酰胺酶抑制剂阿维巴坦和广谱头孢菌素头孢他啶组成的复方制剂。目前尚无已发表的病例报告或研究评估头孢他啶-阿维巴坦在儿科重症患者中的应用。我们报告了一例在重症监护病房（ICU）收治的14岁男孩（体重50千克）因肺炎克雷伯菌（KP）导致的感染性休克成功治疗的病例。

相似文献

1
Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient.头孢他啶-阿维巴坦成功治疗一名儿科重症患者的KPC-MDR败血症性休克。
IDCases. 2019 Sep 5;18:e00634. doi: 10.1016/j.idcr.2019.e00634. eCollection 2019.
2
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.头孢他啶-阿维巴坦与不同抗菌药物联合对产KPC肺炎克雷伯菌临床分离株的体外相互作用
Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.
3
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.头孢他啶-阿维巴坦挽救治疗产碳青霉烯酶肺炎克雷伯菌引起的感染患者的疗效。
Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492.
4
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
5
Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.在接受持续静脉-静脉血液透析滤过治疗铜绿假单胞菌肺炎的危重症患者中，头孢他啶-阿维巴坦的稳态血清浓度和推荐剂量。
Pharmacotherapy. 2019 Dec;39(12):1216-1222. doi: 10.1002/phar.2338. Epub 2019 Oct 31.
6
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.使用头孢他啶/阿维巴坦治疗复杂碳青霉烯类耐药肠杆菌科感染：一项结合分子菌株特征的回顾性研究。
Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4.
7
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.碳青霉烯酶 2（KPC-2），在 Ambler 位置 Asp179 的取代以及对头孢他啶-阿维巴坦的耐药性：β-内酰胺酶蛋白质工程产生独特的抗生素耐药表型。
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
8
Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients.重症监护病房患者中由耐多药鲍曼不动杆菌或产碳青霉烯酶肺炎克雷伯菌引起的感染性休克比较。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02562-17. Print 2018 Jun.
9
OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.OXA-48 介导的头孢他啶-阿维巴坦耐药与进化权衡有关。
mSphere. 2019 Mar 27;4(2):e00024-19. doi: 10.1128/mSphere.00024-19.
10
Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.阿维巴坦+头孢他啶治疗医院获得性肺炎的药代动力学药物评价
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):331-340. doi: 10.1080/17425255.2018.1434142. Epub 2018 Jan 31.

引用本文的文献

1
Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development.头孢他啶-阿维巴坦在患有复杂慢性病的儿科患者难治性或复发性感染病例系列中的应用：有效性及未出现耐药性发展情况
Antibiotics (Basel). 2024 Jun 27;13(7):598. doi: 10.3390/antibiotics13070598.
2
New Antimicrobials for the Treatment of Neonatal Sepsis Caused by Multi-Drug-Resistant Bacteria: A Systematic Review.用于治疗多重耐药菌引起的新生儿败血症的新型抗菌药物：一项系统评价
Antibiotics (Basel). 2023 May 24;12(6):956. doi: 10.3390/antibiotics12060956.
3
Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports.静脉注射头孢他啶-阿维巴坦治疗耐碳青霉烯类肠杆菌科细菌感染的极早产儿：两例报告
J Pediatr Pharmacol Ther. 2022;27(2):192-197. doi: 10.5863/1551-6776-27.2.192. Epub 2022 Feb 9.

本文引用的文献

1
Pharmacokinetic Variability in Pediatrics and Intensive Care: Toward a Personalized Dosing Approach.儿科与重症监护中的药代动力学变异性：迈向个性化给药方法
J Pharm Pharm Sci. 2018;21(1):354-362. doi: 10.18433/jpps30082.
2
Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015).头孢他啶-阿维巴坦的抗菌活性和谱在测试儿科患者的革兰氏阴性菌时的结果：来自 INFORM 监测计划（美国，2011-2015 年）。
Pediatr Infect Dis J. 2018 Jun;37(6):549-554. doi: 10.1097/INF.0000000000001859.
3
Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets.从参加头孢他啶-阿维巴坦治疗复杂性腹腔内感染3期试验的患者中分离出的需氧革兰氏阴性病原体的分子β-内酰胺酶特征，并针对敏感和耐药亚组分析疗效。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02447-16. Print 2017 Jun.
4
Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?危重新生儿和儿科患者抗生素给药的不确定性：微量采样能否提供答案？
Clin Ther. 2016 Sep;38(9):1961-75. doi: 10.1016/j.clinthera.2016.07.093. Epub 2016 Aug 17.
5
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.评估单剂量头孢他啶-阿维巴坦在住院儿科患者中的药代动力学特征、安全性和耐受性的I期研究
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6252-9. doi: 10.1128/AAC.00862-16. Print 2016 Oct.
6
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.头孢他啶/阿维巴坦聚焦：耐多药革兰氏阴性菌感染的新选择。
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
7
A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.β-内酰胺酶抑制剂复方制剂对抗多重耐药革兰氏阴性病原体的卷土重来。
Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Epub 2015 Sep 25.
8
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.头孢他啶-阿维巴坦：一种新型头孢菌素/β-内酰胺酶抑制剂复方制剂。
Drugs. 2013 Feb;73(2):159-77. doi: 10.1007/s40265-013-0013-7.
9
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.产碳青霉烯酶肺炎克雷伯菌血流感染患者的死亡预测因素及恰当抗菌治疗的影响。
Clin Microbiol Infect. 2011 Dec;17(12):1798-803. doi: 10.1111/j.1469-0691.2011.03514.x. Epub 2011 May 20.